Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	2.39B
Revenue (ttm)	665.13M
Net Income (ttm)	64.50M
Shares Out	56.07M
EPS (ttm)	1.14
PE Ratio	37.26
Forward PE	19.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,065,341
Open	41.79
Previous Close	41.24
Day's Range	41.79 - 42.93
52-Week Range	29.16 - 43.62
Beta	0.74
Analysts	Buy
Price Target	41.00 (-3.8%)
Earnings Date	Aug 5, 2025

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 674
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN
• Website: https://www.supernus.com

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Analyst Forecast

According to 2 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price target is $41.0, which is a decrease of -3.80% from the latest price.

Price Target

$41.0

(-3.80% downside)

Analyst Consensus: Buy